Humana (NYSE:HUM) Rating Increased to Buy at StockNews.com

Humana (NYSE:HUM) was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Monday.

Other equities research analysts have also recently issued research reports about the stock. Piper Sandler lifted their price target on shares of Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Cantor Fitzgerald reiterated a “neutral” rating and set a $290.00 price target on shares of Humana in a research note on Wednesday, February 12th. Truist Financial lifted their price objective on Humana from $260.00 to $290.00 and gave the stock a “hold” rating in a report on Monday, January 6th. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Finally, Barclays boosted their price target on shares of Humana from $255.00 to $270.00 and gave the company an “equal weight” rating in a research report on Thursday, February 13th. Seventeen analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $280.17.

Humana Stock Performance

Shares of HUM traded up $1.65 on Monday, reaching $255.42. 1,806,769 shares of the company’s stock traded hands, compared to its average volume of 1,722,999. The stock’s 50 day simple moving average is $266.73 and its two-hundred day simple moving average is $271.15. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana has a 52-week low of $213.31 and a 52-week high of $406.46. The stock has a market cap of $30.83 billion, a PE ratio of 25.67, a PEG ratio of 2.05 and a beta of 0.62.

Humana (NYSE:HUM) last released its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a return on equity of 11.70% and a net margin of 1.02%. On average, analysts forecast that Humana will post 16.47 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Humana

A number of institutional investors have recently made changes to their positions in the stock. FPC Investment Advisory Inc. purchased a new stake in Humana during the fourth quarter valued at about $27,000. Centricity Wealth Management LLC bought a new stake in Humana in the 4th quarter worth approximately $30,000. LFA Lugano Financial Advisors SA boosted its stake in Humana by 56.3% in the fourth quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after buying an additional 45 shares in the last quarter. OFI Invest Asset Management bought a new position in Humana during the fourth quarter valued at approximately $33,000. Finally, Transce3nd LLC purchased a new position in shares of Humana during the fourth quarter worth approximately $38,000. Institutional investors own 92.38% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.